Search research articles
Contact Us
Filters
Showing results (171-180 of 206) with videos related to
Page
of 21
Sort By:
Frontiers in Neuroscience
|
October 27, 2025
Neural mechanism of HT7 electroacupuncture in myocardial ischemia: critical role of the paraventricular nucleus oxytocin system
Hao-Sheng Wu, Li Zhu, Pan Liu, et al.
Plos One
|
August 23, 2012
Modified recombinant proteins can be exported via the Sec pathway in Escherichia coli
Nan Chen, Fu-Lin Hong, Hai-Hong Wang, et al.
Molecular Cancer Therapeutics
|
August 15, 2014
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation
Vipin Yadav, Teresa F Burke, Lysiane Huber, et al.
Journal of Pancreatic Cancer
|
March 29, 2020
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
Mark H O'Hara, Wells Messersmith, Hedy Kindler, et al.
Journal of Global Antimicrobial Resistance
|
November 9, 2025
The resistance trends in Mycobacterium kansasii pulmonary isolates and identification of risk factors for drug resistance in Taiwan
Sheng-Bin Fan, Hung-Ling Huang, Hung-Pin Tu, et al.
Oncotarget
|
December 22, 2016
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Eliza Vakana, Susan Pratt, Wayne Blosser, et al.
Expert Review of Molecular Diagnostics
|
December 31, 2016
P16 overexpression in BRAF-mutated gastrointestinal stromal tumors
Shan-Shan Shi, Xuan Wang, Qiu-Yuan Xia, et al.
Vaccine
|
December 11, 2012
Enhanced protective immune response to PCV2 subunit vaccine by co-administration of recombinant porcine IFN-γ in mice
Yi-Ping Wang, Dan Liu, Long-Jun Guo, et al.
Molecular Cancer Therapeutics
|
September 9, 2011
A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models
Genshi Zhao, Wei-Ying Li, Daohong Chen, et al.
Plos One
|
March 9, 2016
Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
Sheng-Bin Peng, Xiaoyi Zhang, Donald Paul, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 206) with videos related to
Sort By:
Page
of 21
Frontiers in Neuroscience
|
October 27, 2025
Neural mechanism of HT7 electroacupuncture in myocardial ischemia: critical role of the paraventricular nucleus oxytocin system
Hao-Sheng Wu, Li Zhu, Pan Liu, et al.
Plos One
|
August 23, 2012
Modified recombinant proteins can be exported via the Sec pathway in Escherichia coli
Nan Chen, Fu-Lin Hong, Hai-Hong Wang, et al.
Molecular Cancer Therapeutics
|
August 15, 2014
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation
Vipin Yadav, Teresa F Burke, Lysiane Huber, et al.
Journal of Pancreatic Cancer
|
March 29, 2020
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
Mark H O'Hara, Wells Messersmith, Hedy Kindler, et al.
Journal of Global Antimicrobial Resistance
|
November 9, 2025
The resistance trends in Mycobacterium kansasii pulmonary isolates and identification of risk factors for drug resistance in Taiwan
Sheng-Bin Fan, Hung-Ling Huang, Hung-Pin Tu, et al.
Oncotarget
|
December 22, 2016
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Eliza Vakana, Susan Pratt, Wayne Blosser, et al.
Expert Review of Molecular Diagnostics
|
December 31, 2016
P16 overexpression in BRAF-mutated gastrointestinal stromal tumors
Shan-Shan Shi, Xuan Wang, Qiu-Yuan Xia, et al.
Vaccine
|
December 11, 2012
Enhanced protective immune response to PCV2 subunit vaccine by co-administration of recombinant porcine IFN-γ in mice
Yi-Ping Wang, Dan Liu, Long-Jun Guo, et al.
Molecular Cancer Therapeutics
|
September 9, 2011
A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models
Genshi Zhao, Wei-Ying Li, Daohong Chen, et al.
Plos One
|
March 9, 2016
Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
Sheng-Bin Peng, Xiaoyi Zhang, Donald Paul, et al.
Page
of 21